Status:
ACTIVE_NOT_RECRUITING
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
Lead Sponsor:
Fudan University
Conditions:
Pancretic Cancer
Diabete Mellitus
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
About 80% of patients with pancreatic adenocarcinoma have aberrant fasting blood glucose at the time of diagnosis. The consistent association between pancreatic cancer and diabetes mellitus has long b...
Eligibility Criteria
Inclusion
- Signed informed content obtained prior to treatment
- Age ≥ 18 years and ≤ 80 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Patients must have histologically confirmed pancreatic adenocarcinoma
- History of diabetes mellitus, or newly diagnosed diabetes mellitus according to the American Diabetes Association criteria
- The expected survival after surgery ≥ 3 months
Exclusion
- Active second primary malignancy or history of second primary malignancy
- Patients who have received any form of anti-tumor therapy including surgery, chemotherapy, radiotherapy, interventional chemoembolization, radiofrequency ablation, and molecular targeted therapy
- Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc
- Pregnant or nursing women
- Patients who are unwilling or unable to comply with study procedures
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05306028
Start Date
August 1 2022
End Date
December 31 2025
Last Update
February 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
Shanghai, Shanghai Municipality, China, 200032